Comparative Evaluation of the New HIV VIDAS® DUO AG/AB Assay With DUO Ultra on Well Characterized Participants From the HIV‐1 Acute Infection French ANRS PRIMO Cohort
Abstract
Diagnosing HIV-1 infection as early as the primary infection is crucial. In this context, we performed a comparative evaluation and agreement analysis of the newly proposed serological assay for the combined detection of total antibodies against HIV and P24 antigen (HIV VIDAS® DUO AG/AB, bioMérieux®), with the previously available HIV VIDAS® DUO Ultra assay in the well characterized acute-HIV-infection multicentric ANRS-CO-06-PRIMO Cohort in classification of Fiebig stages combined with confirmatory testing. Samples collected on the day of enrollment in the cohort, between April 2024 and June 2025, were analyzed with both serological assays. We also performed a recency infection assay, an HIV-1 westernblotting and the measurement of HIV-RNA. Acute infection was classified according to Fiebig stages and compared between both assays. All samples (n = 77) were positive with both assays. One major discordance was noted, with a positive antigen and a negative antibody reaction with DUO AG/AB, with an opposite configuration with DUO Ultra. A high proportion of not determinable signals (26% to 68%) was noted with both assays, prompting a difficulty in classifying acute infection stages in the absence of confirmatory assays. The high rate of not determinable signals especially with P24 antigen with both assays demonstrated in our study, could prompt a difficulty in acute infection classification according to Fiebig.
Related
- Hyperphosphatasia With Intellectual Disability (Mabry Syndrome) due to Compound Heterozygous PIGO Variants: First Molecularly Characterized Case in French Guiana: A Case Report and Review of the Literature.
- Lethal Sudan virus infection in IFNAR-/- mice is characterized by key inflammatory features of filovirus disease
- Encephalitic alphavirus infection induces long-term humoral and cell-mediated responses in seropositive participants from Panama
- Evaluation of Model-Informed Precision Dosing of Cefepime in Critically Ill Patients: A French Before–After Study
- Evaluation of the nutritional and digestive impact of irradiation in nasopharyngeal cancers: the French multicenter retrospective DRAKAR study
BibTeX
@article{mchantaf2026comparative,
title = {{Comparative Evaluation of the New HIV VIDAS® DUO AG/AB Assay With DUO Ultra on Well Characterized Participants From the HIV‐1 Acute Infection French ANRS PRIMO Cohort}},
author = {Gilbert Mchantaf and Xavier Maia and Valérie Andriantsoanirina and Océane Dehan and Karl Stefic and Laurent Hocqueloux and Olivier Robineau and Alain Makinson and Cécile Goujard and Laurence Meyer and Véronique Avettand‐fenoel and Anrs Primo Cohort},
journal = {Journal of Medical Virology},
year = {2026},
month = oct,
doi = {10.1002/jmv.70953},
url = {https://hal.science/hal-05845447v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Comparative Evaluation of the New HIV VIDAS® DUO AG/AB Assay With DUO Ultra on Well Characterized Participants From the HIV‐1 Acute Infection French ANRS PRIMO Cohort
AU - Gilbert Mchantaf
AU - Xavier Maia
AU - Valérie Andriantsoanirina
AU - Océane Dehan
AU - Karl Stefic
AU - Laurent Hocqueloux
AU - Olivier Robineau
AU - Alain Makinson
AU - Cécile Goujard
AU - Laurence Meyer
AU - Véronique Avettand‐fenoel
AU - Anrs Primo Cohort
PY - 2026
DA - 2026/10/30
JO - Journal of Medical Virology
DO - 10.1002/jmv.70953
UR - https://hal.science/hal-05845447v1
AB - Diagnosing HIV-1 infection as early as the primary infection is crucial. In this context, we performed a comparative evaluation and agreement analysis of the newly proposed serological assay for the combined detection of total antibodies against HIV and P24 antigen (HIV VIDAS® DUO AG/AB, bioMérieux®), with the previously available HIV VIDAS® DUO Ultra assay in the well characterized acute-HIV-infection multicentric ANRS-CO-06-PRIMO Cohort in classification of Fiebig stages combined with confirmatory testing. Samples collected on the day of enrollment in the cohort, between April 2024 and June 2025, were analyzed with both serological assays. We also performed a recency infection assay, an HIV-1 westernblotting and the measurement of HIV-RNA. Acute infection was classified according to Fiebig stages and compared between both assays. All samples (n = 77) were positive with both assays. One major discordance was noted, with a positive antigen and a negative antibody reaction with DUO AG/AB, with an opposite configuration with DUO Ultra. A high proportion of not determinable signals (26% to 68%) was noted with both assays, prompting a difficulty in classifying acute infection stages in the absence of confirmatory assays. The high rate of not determinable signals especially with P24 antigen with both assays demonstrated in our study, could prompt a difficulty in acute infection classification according to Fiebig.
SN - 0146-6615
SN - 1096-9071
ER -